Provided by Tiger Fintech (Singapore) Pte. Ltd.

Karyopharm Therapeutics

4.39
-0.2200-4.77%
Post-market: 4.600.2100+4.78%16:28 EDT
Volume:36.02K
Turnover:164.32K
Market Cap:37.93M
PE:-0.35
High:4.83
Open:4.69
Low:4.39
Close:4.61
Loading ...

Barclays Sticks to Its Buy Rating for Karyopharm Therapeutics (KPTI)

TIPRANKS
·
20 Feb

Karyopharm Therapeutics Inc (KPTI) Q4 2024 Earnings Call Highlights: Navigating Revenue ...

GuruFocus.com
·
20 Feb

Q4 2024 Karyopharm Therapeutics Inc Earnings Call

Thomson Reuters StreetEvents
·
20 Feb

Karyopharm Therapeutics Faces Financial Uncertainty Amid $1.6 Billion Deficit and Urgent Need for Funding

TIPRANKS
·
20 Feb

Karyopharm Therapeutics (KPTI) Q4 2024 Earnings Call Transcript

Motley Fool Transcribing
·
20 Feb

Karyopharm Therapeutics (KPTI) Reports Q4 Loss, Tops Revenue Estimates

Zacks
·
19 Feb

Karyopharm Therapeutics: Q4 Earnings Snapshot

Associated Press Finance
·
19 Feb

Karyopharm Therapeutics Q4 Net Income USD -30.78 Million

Reuters
·
19 Feb

Karyopharm Expects 2025 Sales Of $140M-$155M Versus Consensus Of $160.55M, With US Xpovio Net Product Revenue Expected To Be $115M-$130M

Benzinga
·
19 Feb

Karyopharm Therapeutics Q4 2024 GAAP EPS $(0.24) Beats $(0.26) Estimate, Sales $30.54M Miss $34.86M Estimate

Benzinga
·
19 Feb

Karyopharm Therapeutics Q4 Operating Expenses USD 61.823 Million

THOMSON REUTERS
·
19 Feb

Karyopharm Reports Fourth Quarter and Full Year 2024 Financial Results, Announces Update to Phase 3 Xport-Ec-042 Trial and Highlights Recent Company Progress

THOMSON REUTERS
·
19 Feb

Karyopharm Reports Fourth Quarter and Full Year 2024 Financial Results, Announces Update to Phase 3 XPORT-EC-042 Trial and Highlights Recent Company Progress

PR Newswire
·
19 Feb

Karyopharm Therapeutics Inc expected to post a loss of 26 cents a share - Earnings Preview

Reuters
·
17 Feb

Analysts Estimate Indivior PLC (INDV) to Report a Decline in Earnings: What to Look Out for

Zacks
·
13 Feb

Karyopharm to Report Fourth Quarter and Full Year 2024 Financial Results on February 19, 2025

PR Newswire
·
12 Feb

Karyopharm Therapeutics Price Target Maintained With a $3.00/Share by RBC Capital

Dow Jones
·
11 Feb

RBC Capital Sticks to Their Buy Rating for Karyopharm Therapeutics (KPTI)

TIPRANKS
·
10 Feb

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PR Newswire
·
04 Feb

Verve Therapeutics (VERV) Moves 18.7% Higher: Will This Strength Last?

Zacks
·
23 Jan